LYRA
Lyra Therapeutics Inc
NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY
$0.71
+0.00% today
Updated 2026-04-30
Market cap
$870050.00
P/E ratio
—
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
—
52W range
$0 – $34
Volume
0.1M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+6.0
Quality
B2.5
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-10.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$16.00
+2169.50%
12-Month target
—
—
Intrinsic (DCF)
$2.53
Margin of safety
+45.85%
Price chart
X-Ray snapshot
Strengths
+ 45.85% below intrinsic value
+ Debt/equity -7.25x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -10.86 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.36M
- Revenue declining -87.20% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $285000.00 | $1.36M | $1.56M | $1.53M | $600000.00 |
| Net income | $-42.41M | $-55.28M | $-62.68M | $-93.44M | $-5.98M |
| EPS | — | — | — | — | $-22.90 |
| Free cash flow | $-29.20M | $-43.55M | $-64.35M | $-72.35M | $-7.36M |
| Profit margin | -14,880.70% | -4,055.61% | -4,023.11% | -6,090.94% | — |
Peer comparison
Smart narrative
Lyra Therapeutics Inc trades at $0.71. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -10.86, it sits in the distress. TTM revenue stands at $600000.00. Our DCF model estimates intrinsic value at $2.53.
Frequently asked questions
What is Lyra Therapeutics Inc's stock price?
Lyra Therapeutics Inc (LYRA) trades at $0.71.
Is Lyra Therapeutics Inc overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell). DCF value $2.53.
What is the price target of Lyra Therapeutics Inc (LYRA)?
The analyst target price is $16.00, representing +2169.5% upside from the current price of $0.71.
What is the intrinsic value of Lyra Therapeutics Inc (LYRA)?
Based on our DCF model, intrinsic value is $2.53, a +45.9% margin of safety versus $0.71.
What is Lyra Therapeutics Inc's revenue?
TTM revenue is $600000.00.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-10.86 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.45x
ROE-404.50%
Beta0.06
50D MA$1.82
200D MA$5.95
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—